



UNIVERSAL
IBOGAINE

TSXV: IBO

OTCQB: IBOGF

FSE: JC4

TRANSFORMING ADDICTION TREATMENT WITH IBOGAINE

SEPTEMBER 7, 2022

UNIVERSAL IBOGAINE STRATEGIC PILLARS

DEVELOPMENT



LICENSING



DELIVERY



DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS

This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to assist the recipient in evaluating Universal Ibogaine Inc. (“UI” or the “Company”). The presentation is not, nor is it construed under any circumstances as a prospectus, a public offering of securities, or an offering memorandum as defined under any applicable securities legislation, as it does not contain all of the information that would normally appear in an offering registered under applicable securities laws. The information contained herein is subject to change without notice and is based on publicly available information, internally developed information and other sources. Where any opinion or belief is expressed herein, it is based on assumptions and limitations mentioned and is an expression of current opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature, arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or reason of reliance on it by any person. This presentation should not be construed as legal, financial or tax advice, as each individual’s circumstances are different, and readers should consult with their own professional advisors. The information contained in this presentation is not directed to person or entities resident in the United States and does not constitute an offer or a solicitation by anyone in the United States (“U.S.”) or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation.

ANY SECURITIES DESCRIBED IN THIS PRESENTATION HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATES OF THE U.S. THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO “U.S. PERSONS” AS SUCH TERM IS DEFINED IN THE REGULATIONS UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.

Certain statements contained or incorporated in this presentation, which deal with the financial condition and results of the Company, may include information, projections and analyses as to future developments which are currently in the planning stage and reflect the current expectations of UI management regarding future growth, results of operations, performance, business prospects and opportunities. Such forward-looking statements, including references to the Company’s treatment protocol and medical research and developments efforts (including in-house and independent pre-clinical and clinical trial plans) involve known and unknown risks and uncertainties that could cause actual events and/or results to differ materially from those estimated and/or anticipated and which may have been implied and/or expressed in such forward-looking statements. No conclusions as to the successful outcome of UI’s ongoing and planned R&D projects are intended or implied nor can they be foreseen or predicted prior to definitive corporate announcements as to their outcome. There is no assurance that UI will obtain projected revenues or income related to ibogaine as these are subject to obtaining regulatory approvals to use ibogaine which requires successful conclusion of clinical trials and subsequent approvals by necessary regulatory and legal agencies in each country the company plans to operate which are inherently uncertain and subject to the uncertainties of clinical trials or the acceptance of the results by regulatory agencies. Opening additional clinics will require additional financing which may not be available to the Company.

CONTENTS

- 1 OUR PURPOSE**
- 2 THE ADDICTION CRISIS**
- 3 IBOGAINE IS THE SOLUTION**
- 4 WHAT IS IBOGAINE & HOW DOES IT WORK**
- 5 IBOGAINE IN THE MAINSTREAM MEDIA**
- 6 UNIVERSAL IBOGAINE'S MISSION & HISTORY**
- 7 STRATEGIC PILLARS & INVESTMENT HIGHLIGHTS**
- 8 CLINICAL TRIAL ROADMAP**
- 9 REVENUE DRIVERS & PROJECTIONS**
- 10 MARKET POTENTIAL & PEER VALUATIONS**
- 11 CAPITAL STRUCTURE**
- 12 ESG RESPONSIBILITY**
- 13 MANAGEMENT & BOARD OF DIRECTORS**



*Driving Value
with Integrity for
our Shareholders*





OUR PURPOSE

Universal Ibogaine plans to deliver Ibogaine as a viable solution to the Addiction and Overdose Crisis, through a proven treatment protocol and global licensing model.



THE ADDICTION CRISIS

Over 100,000 Overdose Deaths in the USA over the last 12 months with opioids accounting for 75%.⁽¹⁾

Drug Overdose is the leading cause of accidental death in the USA.⁽²⁾



THE ADDICTION CRISIS

1 in 5

Canadian adults will experience addiction ⁽³⁾

35 Million

People require professional treatment for addiction globally ⁽⁴⁾

90%

Relapse rate associated with current treatment modalities ⁽⁵⁾

93%

Increase in overdose deaths amongst First Nations communities since 2019 ⁽⁶⁾

\$1.3 Trillion

Annual economic toll of Opioid epidemic in USA ⁽⁷⁾

300%

Annual increase in substance abuse deaths worldwide since 1999 ⁽⁸⁾



IBOGAINE IS THE SOLUTION

Empirical evidence indicates:

- + Painless Drug Detoxification in 18 to 24 hours**
- + Resets the brain to a Pre-addicted state**
- + Removes Drug Cravings for 2 to 4 months**



WHAT IS IBOGAIN?

Ibogaine refers to a naturally occurring psychoactive indole alkaloid. It is derived from the roots of the African rainforest shrub *Tabernaemontana iboga* and part of the Apocynaceae family. Traditionally used by the Bwiti people of Western Africa, ibogaine helped individuals curb fatigue, hunger, and thirst. It was also used as part of spiritual initiation ceremonies.

Ibogaine today is used across the western world. It often helps people alleviate their drug withdrawal symptoms, as well as reduce their drug cravings and lower their risk of relapse. Multiple studies published in peer-reviewed journals highlight the benefits of using ibogaine to treat addiction symptoms related to cocaine, methamphetamine, heroin, and opiate abuse.

Ibogaine for drug addiction treatment is garnering attention worldwide, due in part to the opioid epidemic that has harmed individuals of all ages. Addiction experts and researchers have published monographs that further illustrate the benefits of ibogaine to interrupt drug-dependence disorders.



HOW DOES IBOGAINE WORK?

Ibogaine is a fast-acting, plant derived substance that interrupts drug addiction symptoms. Ibogaine helps a drug dependent person safely and effectively return to their pre-addicted state.

Ibogaine connects with multiple neurotransmitter systems including the sigma-2 receptor commonly associated with cocaine addiction, opioid receptors, as well as serotonin receptors that modulate mood & behaviors.


Ibogaine also metabolizes as noribogaine, a metabolite that stays in the body for up to four months. Noribogaine makes serotonin readily available in the brain. In doing so, noribogaine helps improve mood and address symptoms associated with post-acute withdrawal syndrome (PAWS).

After an ibogaine detox, withdrawal symptoms and cravings are generally eliminated. Research indicates ibogaine alleviates up to 95% of symptoms associated with opioid withdrawal. Ibogaine also helps significantly reduce cravings for alcohol and stimulants.

Ibogaine detox produces an oneirophrenic (dreamlike) state. An individual may experience visions that provide insight into everyday life and address the root cause of addiction. The ibogaine experience does vary from person to person.



NOTHING DOES WHAT IBOGAINE CAN DO




Psychedelics Reopen the social Reward Learning
Critical period: Duration of the open state

Nardou et al, Nature 2019 (9)



IBOGAINE IN THE MAINSTREAM MEDIA



TIME

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

April 2021



Discover Magazine

Ibogaine: The Psychedelic Drug That Could Fight Addiction

July 2021



Forbes

U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment

December 2021



Rolling Stone

How a Psychedelic 12-Step Program Is Saving Lives


May 2021



Harvard Medical School

Back to the future: Psychedelic drugs in psychiatry

June 2021



The Washington Post Magazine

Who Will Benefit From Psychedelic Medicine?

September 2020



The New York Times

The promises and Perils of Psychedelic Health Care

January 2022



UNIVERSAL IBOGAINE'S MISSION

Universal Ibogaine is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.

UI is concurrently developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

HISTORY OF UNIVERSAL IBOGAINE

- Universal Ibogaine was born in 2018 when Canadian financier Shayne Nyquvest met Dr. Alberto Sola, the world's most experienced ibogaine treatment provider.

- Dr. Sola's ibogaine treatment protocol has disrupted addiction by safely administering over 3,700 treatments to patients since 2007.

- Universal Ibogaine was created with the goal of medicalizing ibogaine for addiction treatment in Canada and then globally.

- UI completed a \$6 million equity offering on August 31, 2021 as part of its go-public listing on the TSX Venture Exchange (“TSXV”)

- Universal Ibogaine acquired (August 2021) the operational Kelburn Recovery Center to be used to eventually develop its ibogaine aftercare program.

- UI completed its public listing on the TSXV on **October 5, 2021**, and in 2022 commenced trading on the OTCQB and FSE (Frankfurt) exchanges.



STRATEGIC PILLARS



IBOGAINE DEVELOPMENT

Medicalize ibogaine hydrochloride molecule through clinical trial in Canada for the treatment of opioid use disorder.



LICENSING

License our ibogaine treatment protocol to Detox Centers and Addiction Treatment Facilities around the world.




DELIVERY

Ongoing optimization and delivery of our state-of-the-art treatment programs at our wholly owned and partner facilities globally.




STRATEGIC PILLAR HIGHLIGHTS

Driving Value with Integrity for our Shareholders



CLINICAL TRIAL ROADMAP

DRUG (IBOGAINE) DEVELOPMENT PROGRAM: PROJECTED ROADMAP



MILESTONES

- Secure GMP Semi-Synthetic Ibogaine Hydrochloride
- Pre-CTA* Meeting
- Indigenous Health MOU*
- CTA/NOL*
- Ph2/HPOC Start + Caribbean Clinic
- Clinic 3+ Licensing/ Franchising

ACRONYMS
CTA = Clinic trial application
NOL = No Objection Letter
HPOC = Human Proof of Concept
MOU = Memorandum of Understanding



POTENTIAL FUTURE REVENUE DRIVERS



DRUG MANUFACTURING & DISTRIBUTION

Planned clinical trial in Canada to demonstrate safety and efficacy of our ibogaine based treatment protocol may yield exclusive drug and treatment protocol distribution rights.



LICENSING TREATMENT PROTOCOLS

Scalable monthly recurring revenues through planned global licensing of treatment protocols and drug supply.



CLINIC SUPPORT FEES

Ongoing support of member clinics including R&D, program development, and operational guidance.




REVENUE PROJECTIONS

A summary of the potential financial projections for the initial 5-year period upon commencement of the planned ibogaine Licensing Model (starting in 2025) is as follows:

all \$ in Cdn millions

| <i>Ibogaine Licensing and Related Sales Revenues</i> | YEAR 1 | YEAR 2 | YEAR 3 | YEAR 4 | YEAR 5 | TOTAL |
|---|-------------|-------------|--------------|--------------|--------------|---------------|
| Licensing Fees | 10.0 | 20.0 | 55.0 | 90.0 | 125.0 | 300.0 |
| Support Fees | - | 3.0 | 9.0 | 25.5 | 52.5 | 90.0 |
| Product Sales | 12.5 | 49.9 | 118.6 | 280.8 | 428.2 | 890.0 |
| Gross Revenue | 22.5 | 72.9 | 182.6 | 396.3 | 605.7 | 1280.0 |
| Operating Costs | 6.2 | 25.0 | 59.3 | 140.4 | 214.1 | 445.0 |
| Gross Margin | 16.2 | 47.9 | 123.3 | 255.9 | 391.6 | 835.0 |
| G&A and Licensing | 9.0 | 9.9 | 10.9 | 12.0 | 12.8 | 54.6 |
| Pre Tax Profit | 7.2 | 38.0 | 112.4 | 243.9 | 378.8 | 780.4 |

MARKET POTENTIAL



OPERATING CLINIC – KELBURN RECOVERY CENTER

State of the Art ibogaine aftercare program development site



Fully operational revenue generating addiction treatment center located near Winnipeg MB Canada, acquired in 2021.

INDUSTRY PEER MARKET CAPITALIZATION



Market capitalizations change constantly – these stats are provided as at August 18 2022 and are provided solely to indicate the names of some of our industry peer group, and their relative size. It is not intended to infer any conclusion as to potential valuations.

CAPITAL STRUCTURE

| TOTALS AS AT AUGUST 18, 2022 | EXERCISE PRICE | TERM/EXPIRY | TOTAL # (MILLIONS) |
|--|----------------|-----------------|--------------------|
| SHARES ISSUED AND OUTSTANDING | NOTE 1) | | 190.7 |
| ADDITIONAL SHARES RESERVED FOR ISSUANCE | | | |
| OPTIONS (BROKERS AND OTHERS) | 0.10 | TO AUG 31, 2023 | 4.8 |
| OPTIONS (DIRECTORS, OFFICERS AND KEY PEOPLE) | 0.25 | 5 to 10 YEARS | 12.0 |
| PERFORMANCE SHARES - DIRECTORS | NOTE 2) | N/A | 1.3 |
| ADVISOR WARRANTS | 0.25 | DEC 31, 2024 | 6.5 |
| SHARE PURCHASE WARRANTS (5 YEAR TERM) | NOTE 3) | AUG 31, 2026 | 51.3 |
| TOTAL SHARES RESERVED | | | 75.9 |
| FULLY DILUTED TOTAL | | | 266.6 |

NOTES

1) Includes 30 million shares issued to Clear Sky, 90% of which will be subject to future performance milestones.

2) Future releases based on UI achieving performance milestones including clinical trials.

3) Warrants exercise price of \$0.50 to Aug 31, 2022 then escalating by \$0.25 per year to \$1.50 in year 5 (Expiry August 31, 2026).

ESG RESPONSIBILITY



ENVIRONMENT

- UI will pursue a semi-synthetic drug supply using plant derived source while preserving the iboga root for indigenous cultural use

SOCIAL

- Commitment to both Purpose and Profit
- Universal Ibogaine is a Pure Play Social Impact Organization

GOVERNANCE

- Diverse and Inclusive Corporate Culture
- Gender and Cultural Diversity on the Board
- Economic Integrity & Commitment to Indigenous Cultures



MANAGEMENT TEAM



NICK KAROS
Chief Executive Officer



GREG LEAVENS
Chief Financial Officer



DR. IAN RABB
Chief Clinics Officer



JULIE DUMOUCHEL
Director Clinical Trials



HIRPAL HUNDIAL
Director Clinical Services



DUGAN SELKIRK
Communications & Investor Relations



BOARD OF DIRECTORS



CHIEF IAN CAMPBELL, MBA
Chairman



ALBERTO SOLA MD
Co-Founder and Director



ANTHONY DECRISTOFARO
Director



ROBERT TURNER, ICD.D, MBA
Director



UNIVERSAL
IBOGAINE

TSXV: IBO

OTCQB: IBOGF

FSE: JC4

THANK YOU



UNIVERSAL
IBOGAINE

NICK KAROS CEO

NICK.KAROS@UNIVERSALIBOGAINE.COM

DUGAN SELKIRK INVESTOR RELATIONS

DUGAN.SELKIRK@UNIVERSALIBOGAINE.COM

Sources

1. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm
2. <https://pubmed.ncbi.nlm.nih.gov/29262202/#:~:text=Drug%20overdose%20is%20the%20leading%20cause%20of%20accidental,and%20about%2091%20opioid%20overdose%20deaths%20every%20day>
3. <https://www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics#:~:text=In%20any%20given%20year%2C%201,mental%20illness%20or%20addiction%20problem.>
4. https://www.unodc.org/unodc/en/frontpage/2019/June/world-drug-report-2019_-35-million-people-worldwide-suffer-from-drug-use-disorders-while-only-1-in-7-people-receive-treatment.html
5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855417/#:~:text=Despite%20detoxification%20combined%20with%20psychosocial,remain%20at%2090%25%20or%20higher.>
6. <https://www.fnha.ca/Documents/FNHA-First-Nations-in-BC-and-the-Overdose-Crisis-Infographic.pdf>
7. <https://www.forbes.com/sites/katiejennings/2022/02/04/economic-toll-of-opioid-epidemic-13-trillion-a-year/?sh=263aac142792>
8. <https://www.cdc.gov/drugoverdose/epidemic/index.html>
9. <https://www.nature.com/articles/s41586-019-1075-9>
10. <https://www.globenewswire.com/news-release/2020/02/20/1988216/0/en/Drug-Addiction-Treatment-Market-To-Reach-USD-31-17-Billion-By-2027-Reports-And-Data.html>